Moonlight Therapeutics raised new private funding from SOSV to support clinical development of MOON101 and received a $3,000,000 cooperative grant from the National Institute of Allergy and Infectious Diseases to fund the SURVEYOR trial and expand its pipeline.
Comments
Want to join the conversation?
Loading comments...